Codexis

Codexis was incorporated in 2002 by Maxygen to develop an enzyme engineering technology platform, completing a spin-off in 2010 as a separate publicly-listed company on the NASDAQ exchange. Today it has three major focus areas: supplying engineered enzymes to commercial customers in pharmaceutical manufacturing, food ingredient manufacturing, and other industrial areas; licensing its CodeEvolver technology package to companies interested in engineering their own enzymes in-house; and developing a clinical portfolio of biologics created from its technology platform. In 2018 the company expects to generate $60 million to $63 million in revenue for the full year, including $25 million to $28 million from products in commercial supply contracts.

Codexis was incorporated in 2002 by Maxygen to develop an enzyme engineering technology platform, completing a spin-off in 2010 as a separate publicly-listed company on the NASDAQ exchange. Today it has three major focus areas: supplying engineered enzymes to commercial customers in pharmaceutical manufacturing, food ingredient manufacturing, and other industrial areas; licensing its CodeEvolver technology package to companies interested in engineering their own enzymes; and developing a clinical portfolio of biologics created from its technology platform. In 2018 the company expects to generate $60 million to $63 million in revenue for the full year, including $25 million to $28 million from products in commercial supply contracts.